Loss of the phosphatase and tensin homolog (PTEN) tumor suppressor gene is one of the most common genomic alteration in PCa, and it has been consistently reported to be associated with adverse clinical outcomes (reviewed in [15]). The gene discussed is PTEN; the disease is posterior cortical atrophy.